 |
0 Products |  |
0 Diseases | | 0 Products |
|
0 Trials |  |
60 News |  |
- | aurora A inhibitor / Elara
Journal: A selective Aurora-A 5'-UTR siRNA inhibits tumor growth and metastasis. (Pubmed Central) - Aug 12, 2020
Mice orthotopically injected with colorectal cancer cells, LNA-siRNA-2 treatment not only inhibited the tumor growth but also blocked liver and lung metastasis. The results of our study suggest that LNA-siRNA-2 has the potential to be a novel therapeutic agent for cancer treatment.
- || EL102 / Elara
"La interpretación de @HLGatell sobre las palabras de @DrTedros es errónea: nunca nadie ha pedido que se hagan pruebas para todos los habitantes. Se necesitan más pruebas para tener una imagen más clara de la pandemia": @abanav en #LaPrimeradeMVS por el 102.5 FM y @MVStvOficial (Twitter) - Jul 3, 2020
- | tozasertib (MK-0457) / Vertex, Merck (MSD), aurora A inhibitor / Elara
Journal: Synthesis and identification of 2,4-bisanilinopyrimidines bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential Aurora A inhibitors. (Pubmed Central) - Oct 18, 2019
Mechanistic studies revealed that 10a disrupt the spindle formation, block the cell cycle progression in the G2/M phase and induce apoptosis in HeLa cell. These results suggested that the produced series of compounds are potential anticancer agents for further development as selective Aurora A inhibitors.
- | paclitaxel / Generic Mfg.
Journal: Aurora A kinase activity is required to maintain the spindle assembly checkpoint active during pro-metaphase. (Pubmed Central) - Oct 18, 2019
We observed that a loss of Aurora A activity directly affects SAC function, that Aurora A is essential for maintaining the checkpoint protein Mad2 on unattached kinetochores, and that inhibition of Aurora A leads to SAC extinction, even in the presence of nocodazole or taxol. This is a new finding that should affect the way Aurora A inhibitors are used in cancer treatments.
- | aurora A inhibitor / Elara, alisertib (MLN8237) / Takeda
Clinical, Journal: Aurora-A inhibition eliminates myeloid cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in breast cancer. (Pubmed Central) - Aug 28, 2019
Intriguingly, alisertib combined with PD-L1 blockade showed synergistic efficacy in the treatment of mammary tumors. These results detail the effects of Aurora-A inhibition on the immune microenvironment and provide a novel chemo-immunotherapy strategy for advanced breast cancers.
- | aurora A inhibitor / Elara, alisertib (MLN8237) / Takeda
Journal: Aurora A regulates the architecture of the Golgi apparatus. (Pubmed Central) - Apr 26, 2019
Knockdown or inhibition of Aurora A also led to aberrant integrity of centrosome and Golgi apparatus during interphase. These results suggest that Aurora A activity is involved in the maintenance of Golgi architecture and the relationship between the Golgi apparatus and centrosome.